NCT06723691

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the influence of HRS9531 injection on gastric emptying and pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Acetaminophen	Acetaminophen
DRUG	Metformin	Metformin
DRUG	Warfarin	Warfarin
DRUG	Atorvastatin	Atorvastatin
DRUG	Digoxin	Digoxin
DRUG	HRS9531	HRS9531

Timeline

• Start date: 2024-12-18
• Primary completion: 2025-06-09
• Completion: 2025-06-09
• First posted: 2024-12-09
• Last updated: 2025-06-22

Locations

1 site across 1 country: China